Diet and exercise ± psychological therapy ± drug therapy
Diet and exercise alone typically produces a modest decrease (5% to 10%) in body weight over the short term, but the relapse rate can reach beyond 50%, depending on the length of the follow-up period.[101]Shaw K, Gennat H, O'Rourke P, et al. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003817.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003817.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/17054187?tool=bestpractice.com
[213]Wadden TA, Butryn ML, Byrne KJ. Efficacy of lifestyle modification for long-term weight control. Obes Res. 2004 Dec;12(suppl):151-62S.
https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2004.282
http://www.ncbi.nlm.nih.gov/pubmed/15687411?tool=bestpractice.com
[214]Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007 May;132(6):2226-38.
http://www.ncbi.nlm.nih.gov/pubmed/17498514?tool=bestpractice.com
Adding psychological therapy to diet and exercise can produce a small but statistically significant increase in weight loss, but long-term durability of the weight loss is still poor.[215]Blaine BE, Rodman J, Newman JM. Weight loss treatment and psychological well-being: a review and meta-analysis. J Health Psychol. 2007 Jan;12(1):66-82.
http://www.ncbi.nlm.nih.gov/pubmed/17158841?tool=bestpractice.com
Historically, pharmacotherapy for obesity has had modest short-term efficacy but a high attrition rate and a lack of long-term efficacy.[216]Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007 Jan 6;369(9555):71-7.
http://www.ncbi.nlm.nih.gov/pubmed/17208644?tool=bestpractice.com
Newer drugs approved for long-term use (e.g., semaglutide) are more effective, but adverse effects are still common and evidence suggests that patients may regain weight and see reversal of cardiometabolic improvements if treatment is stopped.[128]Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022 Nov;163(5):1198-1225.
https://www.gastrojournal.org/article/S0016-5085(22)01026-5/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
http://www.ncbi.nlm.nih.gov/pubmed/36273831?tool=bestpractice.com
[217]Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-64.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252
http://www.ncbi.nlm.nih.gov/pubmed/35441470?tool=bestpractice.com
Overall, reported weight loss in clinical trials was between 3% and 10.8% higher in pharmacotherapy groups, and treatment discontinuation ranged from 34 to 219 per 1000.[128]Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022 Nov;163(5):1198-1225.
https://www.gastrojournal.org/article/S0016-5085(22)01026-5/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
http://www.ncbi.nlm.nih.gov/pubmed/36273831?tool=bestpractice.com
Surgical therapy
Bariatric surgery has the best efficacy, and should be considered for patients with more severe obesity, or patients with obesity and persistent poorly controlled weight-related comorbidities despite non-surgical attempts at management.[170]American Society for Metabolic and Bariatric Surgery. Metabolic and bariatric surgery fact sheet. July 2021 [internet publication].
https://asmbs.org/resources/metabolic-and-bariatric-surgery
[173]Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Obes Surg. 2023 Jan;33(1):3-14.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834364
http://www.ncbi.nlm.nih.gov/pubmed/36336720?tool=bestpractice.com
A review of 85,000 previously published cases reported 30-day mortality in all types of bariatric surgery to be 0.28%, with differing rates in subgroup analysis.[218]Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007 Oct;142(4):621-32.
http://www.ncbi.nlm.nih.gov/pubmed/17950357?tool=bestpractice.com
Biliopancreatic diversion with duodenal switch produces the greatest weight loss (≥100% excess body weight) but is complicated by significant protein and vitamin deficiency.
Gastric bypass produces the best balance between weight loss and health of the patient.[219]DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007 May 24;356(21):2176-83.
http://www.ncbi.nlm.nih.gov/pubmed/17522401?tool=bestpractice.com
In experienced hands, with good patient follow-up, patients achieve approximately 60% to 75% excess body weight loss (EBWL). European gastric bands achieve approximately 40% to 50% EBWL.[220]Favretti F, Segato G, Ashton D, et al. Laparoscopic adjustable gastric banding in 1,791 consecutive obese patients: 12-year results. Obes Surg. 2007 Feb;17(2):168-75.
http://www.ncbi.nlm.nih.gov/pubmed/17476867?tool=bestpractice.com
[221]Sjöström L, Lindroos AK, Peltonen M, et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004 Dec 23;351(26):2683-93.
https://www.nejm.org/doi/full/10.1056/NEJMoa035622
http://www.ncbi.nlm.nih.gov/pubmed/15616203?tool=bestpractice.com
Long-term efficacy and safety data in the US are not available for gastric banding. Short-term results for sleeve gastrectomy are promising, with results of 50% to 60% EBWL.[181]ASMBS Clinical Issues Committee. Updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis. 2012 May-Jun;8(3):e21-6.
http://www.ncbi.nlm.nih.gov/pubmed/22417852?tool=bestpractice.com
[222]Frezza EE. Laparoscopic vertical sleeve gastrectomy for morbid obesity: the future procedure of choice? Surg Today. 2007;37(4):275-81.
http://www.ncbi.nlm.nih.gov/pubmed/17387557?tool=bestpractice.com
[223]Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Obes Surg. 2010 Aug;20(8):1171-7.
http://www.ncbi.nlm.nih.gov/pubmed/19632646?tool=bestpractice.com
[224]Shi X, Karmali S, Sharma AM, et al. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010 Aug;20(8):1171-7.
http://www.ncbi.nlm.nih.gov/pubmed/20379795?tool=bestpractice.com
[225]Sarkhosh K, Birch DW, Shi X, et al. The impact of sleeve gastrectomy on hypertension: a systematic review. Obes Surg. 2012 May;22(5):832-7.
http://www.ncbi.nlm.nih.gov/pubmed/22350987?tool=bestpractice.com
Revision to decrease the size of the gastric pouch, gastrojejunostomy, or addition of a malabsorptive procedure to a purely restrictive procedure can be done for surgical failures, although the evidence for this is controversial. Studies have shown that revision of a restrictive procedure to incorporate malabsorption results in greater weight loss than purely restrictive procedures alone.[226]Frantzides CT, Alexander B, Frantzides AT. Laparoscopic revision of failed bariatric procedures. JSLS. 2019 Jan-Mar;23(1):e2018.00074.
https://www.doi.org/10.4293/JSLS.2018.00074
http://www.ncbi.nlm.nih.gov/pubmed/30675090?tool=bestpractice.com